Keros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) dropped 2.7% during trading on Tuesday after Truist Financial lowered their price target on the stock from $100.00 to $43.00. Truist Financial currently has a buy rating on the stock. Keros Therapeutics traded as low as $16.63 and last traded at $16.65. Approximately 211,223 shares were traded during mid-day trading, a decline of 57% from the average daily volume of 487,966 shares. The stock had previously closed at $17.12.
A number of other brokerages have also recently commented on KROS. Bank of America reduced their price objective on Keros Therapeutics from $81.00 to $76.00 and set a "buy" rating for the company in a research note on Thursday, September 12th. William Blair downgraded shares of Keros Therapeutics from an "outperform" rating to a "market perform" rating in a research report on Thursday, December 12th. BTIG Research downgraded shares of Keros Therapeutics from a "buy" rating to a "neutral" rating in a report on Thursday, December 12th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Keros Therapeutics in a research note on Friday, November 22nd. Finally, Guggenheim downgraded shares of Keros Therapeutics from a "buy" rating to a "neutral" rating in a research report on Monday, December 16th. Four investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, Keros Therapeutics has a consensus rating of "Moderate Buy" and a consensus price target of $75.00.
Read Our Latest Report on KROS
Institutional Trading of Keros Therapeutics
Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. KBC Group NV raised its position in shares of Keros Therapeutics by 52.0% during the 3rd quarter. KBC Group NV now owns 1,263 shares of the company's stock valued at $73,000 after buying an additional 432 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in Keros Therapeutics by 26.0% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company's stock worth $77,000 after acquiring an additional 280 shares during the last quarter. Values First Advisors Inc. purchased a new stake in Keros Therapeutics during the third quarter valued at approximately $89,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Keros Therapeutics in the 2nd quarter valued at approximately $128,000. Finally, LMR Partners LLP bought a new stake in shares of Keros Therapeutics in the 3rd quarter valued at approximately $213,000. Institutional investors own 71.56% of the company's stock.
Keros Therapeutics Stock Performance
The stock has a market cap of $676.87 million, a PE ratio of -3.21 and a beta of 1.20. The stock has a fifty day moving average price of $54.10 and a 200 day moving average price of $51.40.
Keros Therapeutics (NASDAQ:KROS - Get Free Report) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($1.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.28) by ($0.13). The firm had revenue of $0.39 million during the quarter. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. Keros Therapeutics's revenue was up 4750.0% compared to the same quarter last year. During the same period in the prior year, the firm posted ($1.33) earnings per share. As a group, equities analysts anticipate that Keros Therapeutics, Inc. will post -5.26 earnings per share for the current fiscal year.
About Keros Therapeutics
(
Get Free Report)
Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.
Further Reading
Before you consider Keros Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Keros Therapeutics wasn't on the list.
While Keros Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
